Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 32
Summary
- Conditions
- Advanced Cancer
- Basal Cell Carcinoma
- Breast Cancer
- Prostate Cancer Metastatic
- Cancer of Stomach
- Colo-rectal Cancer
- Solid Carcinoma of Stomach
- Sarcoma
- Cutaneous Squamous Cell Carcinoma
- Cutaneous T Cell Lymphoma
- Gastric Cancer
- Head and Neck Squamous Cell Carcinoma
- Solid Tumor
- Solid Carcinoma
- Lymphoma
- Pancreatic Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This Phase I study is an open-label, dose-escalation trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of the novel anti-cancer compound, GZ17-6.02. GZ17-6.02 is administered orally to patients with advanced solid tumors or lymphoma.
This Phase I study is an open-label, dose-escalation trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of the novel anti-cancer compound, GZ17-6.02. GZ17-6.02 is administered orally to patients with advanced solid tumors or lymphoma.
Tracking Information
- NCT #
- NCT03775525
- Collaborators
- Translational Drug Development
- Investigators
- Study Director: Kathryn Gazarik Translational Drug Development
Get Well Soon